Objective
To assess the potential role of positron emission tomography (PET) with 2-[18F]lfluoro-2-deoxy-D-glucose (FDG) in patients with unexplained rising carcinoembryonic antigen (CEA) levels after the treatment of colorectal cancer.
Background
A rising CEA level after the resection of colorectal cancer is an early indicator of tumor recurrence. However, conventional imaging techniques have limited sensitivity for detecting recurrent disease in such patients. Especially after surgical intervention, FDG-PET is rapidly gaining an important role in establishing the extent of disease in the oncology patient.
Methods
Twenty-two patients with abnormal CEA levels and normal results of conventional methods of tumor detection were studied with FDG-PET. The PET results were compared with pathologic findings (n = 9) and long-term radiologic and clinical follow-up (n = 13).
Results
FDG-PET was abnormal in 17 of 22 patients. Tissue sampling was available in 7 of these 17 patients; all of these had recurrent disease. Definitive curative surgical intervention was performed in four patients. Subsequent dedicated imaging findings and clinical course confirmed the presence of extensive disease in 8 of the remaining 10 patients; the PET results in the other 2 patients were considered falsely positive. FDG-PET was negative in 5 of 22 patients. No disease was found by tissue sampling (n = 2) and clinical follow-up (n = 3). Overall, the positive-predictive value for PET was 89%, (15 of 17) and the negative-predictive value was 100% (5 of 5).
Conclusions
When conventional examinations are normal, FDG-PET is a valuable imaging tool in patients who have a rising CEA level after colorectal surgery. 5 .0 ng/mL (mean 25 ng/mL) and had normal results of imaging studies, endoscopy, and physical examinations. All 22 patients had normal CEA plasma levels after the surgical resections of their primary tumors, but subsequently had developed a serial rise in their CEA plasma levels on routine follow-up examinations.
Before PET, all of the patients with a history of rectal or rectosigmoid carcinoma underwent CT of the chest, abdomen, and pelvis, while patients with a prior history of colon cancer had CT of the abdomen and the pelvis. The CT examinations were performed no more than 4 weeks before the PET on a fourth-generation CT unit (Siemens Somatom + or Somatom +S). Images of the chest and upper abdomen were obtained from the neck to below the level of the liver using 10-mm contiguous slices. Oral contrast (400-500 mL) was administered before scanning. The CT examinations were interpreted in a routine clinical fashion. Image processing and reconstruction were performed on a SUN (SUN Microsystems, Inc. Mountain View, CA) computer workstation. Images were displayed in three orthogonal projections and as whole-body maximum-pixelintensity reprojection images for visual interpretation. All PET images were evaluated qualitatively in a routine clinical fashion, including correlation with CT images; reported abnormalities represented the consensus of at least two nuclear medicine physicians. The results of the PET study were used in planning patient management at the discretion of the referring surgeon.
The medical records, both inpatient and outpatient, were reviewed. The PET results were correlated with histologic findings and long-term radiologic and clinical follow-up periods (shortest follow-up period after PET was 6 months).
Lesions that were seen by PET, but that were not biopsied, were considered to be true-positive findings if the disease became obvious (in the same location as identified by PET) on a follow-up imaging study directed by PET and within 6 months (median 11 months) of the PET examination. Abnormal foci seen on PET that were not verified on follow-up of this duration were considered false-positive findings. When no abnormality was seen on PET, and when further intervention was not performed, this was considered to be a true-negative result, if by other imaging modalities or by clinical follow-up, no disease was identified within 6 months of the PET examination. 
RESULTS
The clinical and pathologic features of our 22 patients are outlined in Table 1 . At the time of PET, the CEA concentrations in these patients ranged from 10 to 45 ng/mL.
Abnormal foci of increased FDG accumulation were seen in 17 of the 22 patients (77%), with one lesion identified in each of 4 patients, and more than one lesion identified in the remaining 13 of these 17 patients. These foci of increased FDG accumulation were identified in several locations; spleen (2 patients), liver (6 patients), pelvis (6 patients), chest (3 patients), abdominal and pelvic nodes (2 patients), and the peritoneum (4 patients).
Results of tissue sampling were available in 7 of these 17 patients, all of whom had recurrent disease. Definitive curative surgical intervention was performed in four patients because the recurrent tumor was confined to a single resectable location; all of these patients had normal CEA concentrations after surgical resection of the recurrent disease. In the remaining three patients, only a single abnormality was biopsied. However, because of the distribution and extent of the abnormal foci in each of these patients, chemotherapy was administered without further surgical intervention.
Tissue sampling was not performed in the other 10 patients with abnormal PET studies. Subsequent dedicated imaging findings and clinical course confirmed the presence of extensive disease in eight of these patients (Table 1) . These patients received chemotherapy because their recurrent disease was not considered amenable to curative resection (Table 1) .
Overall, the positive predictive value for PET was 89% (15 of 17). False-positive results were obtained in two patients. In one of the patients (patient 19), 2 focal areas of increased FDG accumulation in the pelvis were interpreted as suspicious for local recurrence. Subsequent CT showed that these foci represented asymmetric activity in the bowel and in a bladder diverticulum, respectively. In addition, a cystogram and a pelvic examination under general anesthesia did not disclose disease in these areas. This patient is alive and disease free 9 months after the PET study, and her CEA levels has returned to normal. The PET study of the second patient (patient 1) was of suboptimal quality because of the patient's large size, but showed focally increased activity in the dome of the liver that was considered suspicious for metastasis. Extensive further radiologic and clinical evaluation of this patient failed to confirm this abnormality. This patient is alive and well 4 years later. However his plasma CEA levels continue to fluctuate from 45 to 90 ng/mL. FDG-PET was negative for recurrent disease in 5 of the 22 patients. These patients are all alive and disease free, with follow-up intervals ranging from 9 to 24 months. In two of these patients, biopsy at the anastomotic site was negative for tumor recurrence. In the remaining three patients, clinical follow-up and radiologic examinations failed to document disease progression. The plasma CEA levels decreased to normal in four of these patients and has remained stable but elevated in one patient. The negative predictive value for PET was thus 100%.
DISCUSSION
In recent years, FDG-PET has emerged as an extremely useful technique in oncologic practice.4'5 Because PET detects regional metabolic abnormalities, rather than morphological abnormalities, it appears to be particularly helpful for assessing patients suspected to have tumor recurrence and in patients whom posttherapeutic alterations in anatomy make it difficult to interpret conventional imaging studies. Moreover, it appears that PET is more sensitive than conventional cross-sectional imaging methods for detecting recurrent disease and distant metastases. For example, the reported sensitivity and specificity of CT for detection of liver metastases has been as low as 42% and 50%.14 CT portography is highly sensitive (80%-90%), but has a considerable rate of false-positive findings. '4 Recent series have shown that FDG-PET has an overall sensitivity of 93% to 100% and a specificity of 78% to 100% in the detection of recurrent disease in patients treated for colorectal cancer.4-6,8-10"12 '15 In one report, PET altered clinical management in 40% of the patients with recurrent disease.8
The use of CEA monitoring in the follow-up evaluation of patients with treated colorectal cancer is based on the general, well-documented principles that elevated CEA concentrations will revert to normal after curative resection, but will persist if the residual tumor is left behind. In addition, an increase in CEA concentration on serial measurements after curative surgery is indicative of tumor recurrence. ' 
